Summary
According to APO Research, the global Recombinant DNA Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Recombinant DNA Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Recombinant DNA Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Recombinant DNA Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Recombinant DNA Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Recombinant DNA Vaccine market include Boehringer-Ingelheim, Elanco, Indian Immunologicals, Plumbline Life Sciences, Zoties, GSK, Merck and Sanofi, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Recombinant DNA Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Recombinant DNA Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Recombinant DNA Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant DNA Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Recombinant DNA Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Recombinant DNA Vaccine sales, projected growth trends, production technology, application and end-user industry.
Recombinant DNA Vaccine Segment by Company
Boehringer-Ingelheim
Elanco
Indian Immunologicals
Plumbline Life Sciences
Zoties
GSK
Merck
Sanofi
Recombinant DNA Vaccine Segment by Type
Recombinant Protein Vaccine
Gene-Based Vaccine
Recombinant DNA Vaccine Segment by Application
Human
Animal
Recombinant DNA Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Recombinant DNA Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Recombinant DNA Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Recombinant DNA Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Recombinant DNA Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant DNA Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant DNA Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant DNA Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Recombinant DNA Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant DNA Vaccine industry.
Chapter 3: Detailed analysis of Recombinant DNA Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Recombinant DNA Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Recombinant DNA Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
- Market Overview
- Product Definition
- Global Market Growth Prospects
- Global Recombinant DNA Vaccine Sales Value (2020-2031)
- Global Recombinant DNA Vaccine Sales Volume (2020-2031)
- Global Recombinant DNA Vaccine Sales Average Price (2020-2031)
- Assumptions and Limitations
- Study Goals and Objectives
- Recombinant DNA Vaccine Market Dynamics
- Recombinant DNA Vaccine Industry Trends
- Recombinant DNA Vaccine Industry Drivers
- Recombinant DNA Vaccine Industry Opportunities and Challenges
- Recombinant DNA Vaccine Industry Restraints
- Recombinant DNA Vaccine Market by Company
- Global Recombinant DNA Vaccine Company Revenue Ranking in 2024
- Global Recombinant DNA Vaccine Revenue by Company (2020-2025)
- Global Recombinant DNA Vaccine Sales Volume by Company (2020-2025)
- Global Recombinant DNA Vaccine Average Price by Company (2020-2025)
- Global Recombinant DNA Vaccine Company Ranking (2023-2025)
- Global Recombinant DNA Vaccine Company Manufacturing Base and Headquarters
- Global Recombinant DNA Vaccine Company Product Type and Application
- Global Recombinant DNA Vaccine Company Establishment Date
- Market Competitive Analysis
- Global Recombinant DNA Vaccine Market Concentration Ratio (CR5 and HHI)
- Global Top 5 and 10 Company Market Share by Revenue in 2024
- 2024 Recombinant DNA Vaccine Tier 1, Tier 2, and Tier 3 Companies
- Mergers and Acquisitions Expansion
- Recombinant DNA Vaccine Market by Type
- Recombinant DNA Vaccine Type Introduction
- Recombinant Protein Vaccine
- Gene-Based Vaccine
- Global Recombinant DNA Vaccine Sales Volume by Type
- Global Recombinant DNA Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
- Global Recombinant DNA Vaccine Sales Volume by Type (2020-2031)
- Global Recombinant DNA Vaccine Sales Volume Share by Type (2020-2031)
- Global Recombinant DNA Vaccine Sales Value by Type
- Global Recombinant DNA Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
- Global Recombinant DNA Vaccine Sales Value by Type (2020-2031)
- Global Recombinant DNA Vaccine Sales Value Share by Type (2020-2031)
- Recombinant DNA Vaccine Type Introduction
- Recombinant DNA Vaccine Market by Application
- Recombinant DNA Vaccine Application Introduction
- Human
- Animal
- Global Recombinant DNA Vaccine Sales Volume by Application
- Global Recombinant DNA Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
- Global Recombinant DNA Vaccine Sales Volume by Application (2020-2031)
- Global Recombinant DNA Vaccine Sales Volume Share by Application (2020-2031)
- Global Recombinant DNA Vaccine Sales Value by Application
- Global Recombinant DNA Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
- Global Recombinant DNA Vaccine Sales Value by Application (2020-2031)
- Global Recombinant DNA Vaccine Sales Value Share by Application (2020-2031)
- Recombinant DNA Vaccine Application Introduction
- Recombinant DNA Vaccine Regional Sales and Value Analysis
- Global Recombinant DNA Vaccine Sales by Region: 2020 VS 2024 VS 2031
- Global Recombinant DNA Vaccine Sales by Region (2020-2031)
- Global Recombinant DNA Vaccine Sales by Region: 2020-2025
- Global Recombinant DNA Vaccine Sales by Region (2026-2031)
- Global Recombinant DNA Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
- Global Recombinant DNA Vaccine Sales Value by Region (2020-2031)
- Global Recombinant DNA Vaccine Sales Value by Region: 2020-2025
- Global Recombinant DNA Vaccine Sales Value by Region (2026-2031)
- Global Recombinant DNA Vaccine Market Price Analysis by Region (2020-2025)
- North America
- North America Recombinant DNA Vaccine Sales Value (2020-2031)
- North America Recombinant DNA Vaccine Sales Value Share by Country, 2024 VS 2031
- Europe
- Europe Recombinant DNA Vaccine Sales Value (2020-2031)
- Europe Recombinant DNA Vaccine Sales Value Share by Country, 2024 VS 2031
- Asia-Pacific
- Asia-Pacific Recombinant DNA Vaccine Sales Value (2020-2031)
- Asia-Pacific Recombinant DNA Vaccine Sales Value Share by Country, 2024 VS 2031
- South America
- South America Recombinant DNA Vaccine Sales Value (2020-2031)
- South America Recombinant DNA Vaccine Sales Value Share by Country, 2024 VS 2031
- Middle East & Africa
- Middle East & Africa Recombinant DNA Vaccine Sales Value (2020-2031)
- Middle East & Africa Recombinant DNA Vaccine Sales Value Share by Country, 2024 VS 2031
- Recombinant DNA Vaccine Country-level Sales and Value Analysis
- Global Recombinant DNA Vaccine Sales by Country: 2020 VS 2024 VS 2031
- Global Recombinant DNA Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
- Global Recombinant DNA Vaccine Sales by Country (2020-2031)
- Global Recombinant DNA Vaccine Sales by Country (2020-2025)
- Global Recombinant DNA Vaccine Sales by Country (2026-2031)
- Global Recombinant DNA Vaccine Sales Value by Country (2020-2031)
- Global Recombinant DNA Vaccine Sales Value by Country (2020-2025)
- Global Recombinant DNA Vaccine Sales Value by Country (2026-2031)
- USA
- USA Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- USA Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- USA Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Canada
- Canada Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Canada Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Canada Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Mexico
- Mexico Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Mexico Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Mexico Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Germany
- Germany Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Germany Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Germany Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- France
- France Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- France Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- France Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- U.K.
- U.K. Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- U.K. Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- U.K. Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Italy
- Italy Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Italy Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Italy Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Spain
- Spain Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Spain Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Spain Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Russia
- Russia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Russia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Russia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Netherlands
- Netherlands Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Netherlands Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Netherlands Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Nordic Countries
- Nordic Countries Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Nordic Countries Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Nordic Countries Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- China
- China Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- China Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- China Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Japan
- Japan Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Japan Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Japan Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- South Korea
- South Korea Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- South Korea Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- South Korea Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- India
- India Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- India Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- India Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Australia
- Australia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Australia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Australia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Southeast Asia
- Southeast Asia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Southeast Asia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Southeast Asia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Brazil
- Brazil Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Brazil Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Brazil Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Argentina
- Argentina Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Argentina Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Argentina Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Chile
- Chile Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Chile Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Chile Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Colombia
- Colombia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Colombia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Colombia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Peru
- Peru Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Peru Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Peru Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Saudi Arabia
- Saudi Arabia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Saudi Arabia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Saudi Arabia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Israel
- Israel Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Israel Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Israel Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- UAE
- UAE Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- UAE Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- UAE Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Turkey
- Turkey Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Turkey Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Turkey Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Iran
- Iran Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Iran Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Iran Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Egypt
- Egypt Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031)
- Egypt Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031
- Egypt Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031
- Company Profiles
- Boehringer-Ingelheim
- Boehringer-Ingelheim Comapny Information
- Boehringer-Ingelheim Business Overview
- Boehringer-Ingelheim Recombinant DNA Vaccine Sales, Value and Gross Margin (2020-2025)
- Boehringer-Ingelheim Recombinant DNA Vaccine Product Portfolio
- Boehringer-Ingelheim Recent Developments
- Elanco
- Elanco Comapny Information
- Elanco Business Overview
- Elanco Recombinant DNA Vaccine Sales, Value and Gross Margin (2020-2025)
- Elanco Recombinant DNA Vaccine Product Portfolio
- Elanco Recent Developments
- Indian Immunologicals
- Indian Immunologicals Comapny Information
- Indian Immunologicals Business Overview
- Indian Immunologicals Recombinant DNA Vaccine Sales, Value and Gross Margin (2020-2025)
- Indian Immunologicals Recombinant DNA Vaccine Product Portfolio
- Indian Immunologicals Recent Developments
- Plumbline Life Sciences
- Plumbline Life Sciences Comapny Information
- Plumbline Life Sciences Business Overview
- Plumbline Life Sciences Recombinant DNA Vaccine Sales, Value and Gross Margin (2020-2025)
- Plumbline Life Sciences Recombinant DNA Vaccine Product Portfolio
- Plumbline Life Sciences Recent Developments
- Zoties
- Zoties Comapny Information
- Zoties Business Overview
- Zoties Recombinant DNA Vaccine Sales, Value and Gross Margin (2020-2025)
- Zoties Recombinant DNA Vaccine Product Portfolio
- Zoties Recent Developments
- GSK
- GSK Comapny Information
- GSK Business Overview
- GSK Recombinant DNA Vaccine Sales, Value and Gross Margin (2020-2025)
- GSK Recombinant DNA Vaccine Product Portfolio
- GSK Recent Developments
- Merck
- Merck Comapny Information
- Merck Business Overview
- Merck Recombinant DNA Vaccine Sales, Value and Gross Margin (2020-2025)
- Merck Recombinant DNA Vaccine Product Portfolio
- Merck Recent Developments
- Sanofi
- Sanofi Comapny Information
- Sanofi Business Overview
- Sanofi Recombinant DNA Vaccine Sales, Value and Gross Margin (2020-2025)
- Sanofi Recombinant DNA Vaccine Product Portfolio
- Sanofi Recent Developments
- Boehringer-Ingelheim
- Value Chain and Sales Channels Analysis
- Recombinant DNA Vaccine Value Chain Analysis
- Recombinant DNA Vaccine Key Raw Materials
- Raw Materials Key Suppliers
- Manufacturing Cost Structure
- Recombinant DNA Vaccine Sales Mode & Process
- Recombinant DNA Vaccine Sales Channels Analysis
- Direct Comparison with Distribution Share
- Recombinant DNA Vaccine Distributors
- Recombinant DNA Vaccine Customers
- Recombinant DNA Vaccine Value Chain Analysis
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
List of Tables
Table 1 | :Recombinant DNA Vaccine Industry Trends |
Table 2 | :Recombinant DNA Vaccine Industry Drivers |
Table 3 | :Recombinant DNA Vaccine Industry Opportunities and Challenges |
Table 4 | :Recombinant DNA Vaccine Industry Restraints |
Table 5 | :Global Recombinant DNA Vaccine Revenue by Company (US$ Million) & (2020-2025) |
Table 6 | :Global Recombinant DNA Vaccine Revenue Share by Company (2020-2025) |
Table 7 | :Global Recombinant DNA Vaccine Sales Volume by Company (K Units) & (2020-2025) |
Table 8 | :Global Recombinant DNA Vaccine Sales Volume Share by Company (2020-2025) |
Table 9 | :Global Recombinant DNA Vaccine Average Price (US$/Unit) of Company (2020-2025) |
Table 10 | :Global Recombinant DNA Vaccine Company Ranking, (2023-2025) & (USD Million) |
Table 11 | :Global Recombinant DNA Vaccine Key Company Manufacturing Base & Headquarters |
Table 12 | :Global Recombinant DNA Vaccine Company, Product Type & Application |
Table 13 | :Global Recombinant DNA Vaccine Company Establishment Date |
Table 14 | :Global Company Market Concentration Ratio (CR5 and HHI) |
Table 15 | :Global Recombinant DNA Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2024) |
Table 16 | :Mergers & Acquisitions, Expansion |
Table 17 | :Significant Companies of Recombinant Protein Vaccine |
Table 18 | :Significant Companies of Gene-Based Vaccine |
Table 19 | :Global Recombinant DNA Vaccine Sales Volume by Type 2020 VS 2024 VS 2031 (K Units) |
Table 20 | :Global Recombinant DNA Vaccine Sales Volume by Type (2020-2025) & (K Units) |
Table 21 | :Global Recombinant DNA Vaccine Sales Volume by Type (2026-2031) & (K Units) |
Table 22 | :Global Recombinant DNA Vaccine Sales Volume Share by Type (2020-2025) |
Table 23 | :Global Recombinant DNA Vaccine Sales Volume Share by Type (2026-2031) |
Table 24 | :Global Recombinant DNA Vaccine Sales Value by Type 2020 VS 2024 VS 2031 (US$ Million) |
Table 25 | :Global Recombinant DNA Vaccine Sales Value by Type (2020-2025) & (US$ Million) |
Table 26 | :Global Recombinant DNA Vaccine Sales Value by Type (2026-2031) & (US$ Million) |
Table 27 | :Global Recombinant DNA Vaccine Sales Value Share by Type (2020-2025) |
Table 28 | :Global Recombinant DNA Vaccine Sales Value Share by Type (2026-2031) |
Table 29 | :Significant Companies of Human |
Table 30 | :Significant Companies of Animal |
Table 31 | :Global Recombinant DNA Vaccine Sales Volume by Application 2020 VS 2024 VS 2031 (K Units) |
Table 32 | :Global Recombinant DNA Vaccine Sales Volume by Application (2020-2025) & (K Units) |
Table 33 | :Global Recombinant DNA Vaccine Sales Volume by Application (2026-2031) & (K Units) |
Table 34 | :Global Recombinant DNA Vaccine Sales Volume Share by Application (2020-2025) |
Table 35 | :Global Recombinant DNA Vaccine Sales Volume Share by Application (2026-2031) |
Table 36 | :Global Recombinant DNA Vaccine Sales Value by Application 2020 VS 2024 VS 2031 (US$ Million) |
Table 37 | :Global Recombinant DNA Vaccine Sales Value by Application (2020-2025) & (US$ Million) |
Table 38 | :Global Recombinant DNA Vaccine Sales Value by Application (2026-2031) & (US$ Million) |
Table 39 | :Global Recombinant DNA Vaccine Sales Value Share by Application (2020-2025) |
Table 40 | :Global Recombinant DNA Vaccine Sales Value Share by Application (2026-2031) |
Table 41 | :Global Recombinant DNA Vaccine Sales by Region: 2020 VS 2024 VS 2031 (K Units) |
Table 42 | :Global Recombinant DNA Vaccine Sales by Region (2020-2025) & (K Units) |
Table 43 | :Global Recombinant DNA Vaccine Sales Market Share by Region (2020-2025) |
Table 44 | :Global Recombinant DNA Vaccine Sales by Region (2026-2031) & (K Units) |
Table 45 | :Global Recombinant DNA Vaccine Sales Market Share by Region (2026-2031) |
Table 46 | :Global Recombinant DNA Vaccine Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Table 47 | :Global Recombinant DNA Vaccine Sales Value by Region (2020-2025) & (US$ Million) |
Table 48 | :Global Recombinant DNA Vaccine Sales Value Share by Region (2020-2025) |
Table 49 | :Global Recombinant DNA Vaccine Sales Value by Region (2026-2031) & (US$ Million) |
Table 50 | :Global Recombinant DNA Vaccine Sales Value Share by Region (2026-2031) |
Table 51 | :Global Recombinant DNA Vaccine Market Average Price (US$/Unit) by Region (2020-2025) |
Table 52 | :Global Recombinant DNA Vaccine Market Average Price (US$/Unit) by Region (2026-2031) |
Table 53 | :Global Recombinant DNA Vaccine Sales by Country: 2020 VS 2024 VS 2031 (K Units) |
Table 54 | :Global Recombinant DNA Vaccine Sales Value by Country: 2020 VS 2024 VS 2031 (US$ Million) |
Table 55 | :Global Recombinant DNA Vaccine Sales by Country (2020-2025) & (K Units) |
Table 56 | :Global Recombinant DNA Vaccine Sales Market Share by Country (2020-2025) |
Table 57 | :Global Recombinant DNA Vaccine Sales by Country (2026-2031) & (K Units) |
Table 58 | :Global Recombinant DNA Vaccine Sales Market Share by Country (2026-2031) |
Table 59 | :Global Recombinant DNA Vaccine Sales Value by Country (2020-2025) & (US$ Million) |
Table 60 | :Global Recombinant DNA Vaccine Sales Value Market Share by Country (2020-2025) |
Table 61 | :Global Recombinant DNA Vaccine Sales Value by Country (2026-2031) & (US$ Million) |
Table 62 | :Global Recombinant DNA Vaccine Sales Value Market Share by Country (2026-2031) |
Table 63 | :Boehringer-Ingelheim Company Information |
Table 64 | :Boehringer-Ingelheim Business Overview |
Table 65 | :Boehringer-Ingelheim Recombinant DNA Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 66 | :Boehringer-Ingelheim Recombinant DNA Vaccine Product Portfolio |
Table 67 | :Boehringer-Ingelheim Recent Development |
Table 68 | :Elanco Company Information |
Table 69 | :Elanco Business Overview |
Table 70 | :Elanco Recombinant DNA Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 71 | :Elanco Recombinant DNA Vaccine Product Portfolio |
Table 72 | :Elanco Recent Development |
Table 73 | :Indian Immunologicals Company Information |
Table 74 | :Indian Immunologicals Business Overview |
Table 75 | :Indian Immunologicals Recombinant DNA Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 76 | :Indian Immunologicals Recombinant DNA Vaccine Product Portfolio |
Table 77 | :Indian Immunologicals Recent Development |
Table 78 | :Plumbline Life Sciences Company Information |
Table 79 | :Plumbline Life Sciences Business Overview |
Table 80 | :Plumbline Life Sciences Recombinant DNA Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 81 | :Plumbline Life Sciences Recombinant DNA Vaccine Product Portfolio |
Table 82 | :Plumbline Life Sciences Recent Development |
Table 83 | :Zoties Company Information |
Table 84 | :Zoties Business Overview |
Table 85 | :Zoties Recombinant DNA Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 86 | :Zoties Recombinant DNA Vaccine Product Portfolio |
Table 87 | :Zoties Recent Development |
Table 88 | :GSK Company Information |
Table 89 | :GSK Business Overview |
Table 90 | :GSK Recombinant DNA Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 91 | :GSK Recombinant DNA Vaccine Product Portfolio |
Table 92 | :GSK Recent Development |
Table 93 | :Merck Company Information |
Table 94 | :Merck Business Overview |
Table 95 | :Merck Recombinant DNA Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 96 | :Merck Recombinant DNA Vaccine Product Portfolio |
Table 97 | :Merck Recent Development |
Table 98 | :Sanofi Company Information |
Table 99 | :Sanofi Business Overview |
Table 100 | :Sanofi Recombinant DNA Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
Table 101 | :Sanofi Recombinant DNA Vaccine Product Portfolio |
Table 102 | :Sanofi Recent Development |
Table 103 | :Key Raw Materials |
Table 104 | :Raw Materials Key Suppliers |
Table 105 | :Recombinant DNA Vaccine Distributors List |
Table 106 | :Recombinant DNA Vaccine Customers List |
Table 107 | :Research Programs/Design for This Report |
Table 108 | :Authors List of This Report |
Table 109 | :Secondary Sources |
Table 110 | :Primary Sources |
List of Figures
Figure 1 | :Recombinant DNA Vaccine Product Image |
Figure 2 | :Global Recombinant DNA Vaccine Sales Value (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global Recombinant DNA Vaccine Sales Value (2020-2031) & (US$ Million) |
Figure 4 | :Global Recombinant DNA Vaccine Sales (2020-2031) & (K Units) |
Figure 5 | :Global Recombinant DNA Vaccine Sales Average Price (US$/Unit) & (2020-2031) |
Figure 6 | :Global Recombinant DNA Vaccine Company Revenue Ranking in 2024 (US$ Million) |
Figure 7 | :Global Top 5 and 10 Company Market Share by Revenue in 2024 (US$ Million) |
Figure 8 | :Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
Figure 9 | :Recombinant Protein Vaccine Image |
Figure 10 | :Gene-Based Vaccine Image |
Figure 11 | :Global Recombinant DNA Vaccine Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units) |
Figure 12 | :Global Recombinant DNA Vaccine Sales Volume Share 2020 VS 2024 VS 2031 |
Figure 13 | :Global Recombinant DNA Vaccine Sales Volume Share by Type (2020-2031) |
Figure 14 | :Global Recombinant DNA Vaccine Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 15 | :Global Recombinant DNA Vaccine Sales Value Share 2020 VS 2024 VS 2031 |
Figure 16 | :Global Recombinant DNA Vaccine Sales Value Share by Type (2020-2031) |
Figure 17 | :Human Image |
Figure 18 | :Animal Image |
Figure 19 | :Global Recombinant DNA Vaccine Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units) |
Figure 20 | :Global Recombinant DNA Vaccine Sales Volume Share 2020 VS 2024 VS 2031 |
Figure 21 | :Global Recombinant DNA Vaccine Sales Volume Share by Application (2020-2031) |
Figure 22 | :Global Recombinant DNA Vaccine Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 23 | :Global Recombinant DNA Vaccine Sales Value Share 2020 VS 2024 VS 2031 |
Figure 24 | :Global Recombinant DNA Vaccine Sales Value Share by Application (2020-2031) |
Figure 25 | :Global Recombinant DNA Vaccine Sales by Region: 2020 VS 2024 VS 2031 (K Units) |
Figure 26 | :Global Recombinant DNA Vaccine Sales Market Share by Region: 2020 VS 2024 VS 2031 |
Figure 27 | :Global Recombinant DNA Vaccine Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Figure 28 | :Global Recombinant DNA Vaccine Sales Value Share by Region: 2020 VS 2024 VS 2031 |
Figure 29 | :North America Recombinant DNA Vaccine Sales Value (2020-2031) & (US$ Million) |
Figure 30 | :North America Recombinant DNA Vaccine Sales Value Share by Country (%), 2024 VS 2031 |
Figure 31 | :Europe Recombinant DNA Vaccine Sales Value (2020-2031) & (US$ Million) |
Figure 32 | :Europe Recombinant DNA Vaccine Sales Value Share by Country (%), 2024 VS 2031 |
Figure 33 | :Asia-Pacific Recombinant DNA Vaccine Sales Value (2020-2031) & (US$ Million) |
Figure 34 | :Asia-Pacific Recombinant DNA Vaccine Sales Value Share by Country (%), 2024 VS 2031 |
Figure 35 | :South America Recombinant DNA Vaccine Sales Value (2020-2031) & (US$ Million) |
Figure 36 | :South America Recombinant DNA Vaccine Sales Value Share by Country (%), 2024 VS 2031 |
Figure 37 | :Middle East & Africa Recombinant DNA Vaccine Sales Value (2020-2031) & (US$ Million) |
Figure 38 | :Middle East & Africa Recombinant DNA Vaccine Sales Value Share by Country (%), 2024 VS 2031 |
Figure 39 | :USA Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 40 | :USA Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 41 | :USA Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 42 | :Canada Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 43 | :Canada Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 44 | :Canada Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 45 | :Mexico Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 46 | :Mexico Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 47 | :Mexico Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 48 | :Germany Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 49 | :Germany Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 50 | :Germany Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 51 | :France Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 52 | :France Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 53 | :France Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 54 | :U.K. Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 55 | :U.K. Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 56 | :U.K. Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 57 | :Italy Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 58 | :Italy Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 59 | :Italy Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 60 | :Spain Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 61 | :Spain Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 62 | :Spain Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 63 | :Russia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 64 | :Russia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 65 | :Russia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 66 | :Netherlands Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 67 | :Netherlands Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 68 | :Netherlands Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 69 | :Nordic Countries Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 70 | :Nordic Countries Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 71 | :Nordic Countries Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 72 | :China Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 73 | :China Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 74 | :China Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 75 | :Japan Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 76 | :Japan Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 77 | :Japan Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 78 | :South Korea Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 79 | :South Korea Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 80 | :South Korea Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 81 | :India Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 82 | :India Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 83 | :India Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 84 | :Australia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 85 | :Australia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 86 | :Australia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 87 | :Southeast Asia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 88 | :Southeast Asia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 89 | :Southeast Asia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 90 | :Brazil Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 91 | :Brazil Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 92 | :Brazil Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 93 | :Argentina Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 94 | :Argentina Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 95 | :Argentina Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 96 | :Chile Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 97 | :Chile Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 98 | :Chile Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 99 | :Colombia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 100 | :Colombia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 101 | :Colombia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 102 | :Peru Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 103 | :Peru Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 104 | :Peru Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 105 | :Saudi Arabia Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 106 | :Saudi Arabia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 107 | :Saudi Arabia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 108 | :Israel Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 109 | :Israel Arabia Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 110 | :Israel Arabia Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 111 | :UAE Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 112 | :UAE Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 113 | :UAE Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 114 | :Turkey Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 115 | :Turkey Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 116 | :Turkey Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 117 | :Iran Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 118 | :Iran Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 119 | :Iran Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 120 | :Egypt Recombinant DNA Vaccine Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 121 | :Egypt Recombinant DNA Vaccine Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 122 | :Egypt Recombinant DNA Vaccine Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 123 | :Recombinant DNA Vaccine Value Chain |
Figure 124 | :Manufacturing Cost Structure |
Figure 125 | :Recombinant DNA Vaccine Sales Mode & Process |
Figure 126 | :Direct Comparison with Distribution Share |
Figure 127 | :Distributors Profiles |
Figure 128 | :Years Considered |
Figure 129 | :Research Process |
Figure 130 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global Recombinant DNA Vaccine Market Outlook and Growth Opportunities 2025
Pages: 191
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.